The TB Alliance announced today the appointment of three new Scientific Advisors. These professionals bring with them diverse areas of expertise from the pharmaceutical industry and academia that will help guide the TB Alliance’s scientific decisions in its pursuit to discover and develop new and improved tuberculosis (TB) treatments for millions.
The TB Alliance is a not-for-profit product development partnership searching for better, faster cures for tuberculosis. Last year, 1.7 million people were killed by TB, globally.
The TB Alliance’s Scientific Advisory Committee provides technical expertise on drug research, development, manufacturing, and distribution, as well as other medical and scientific issues. It consists of scientific experts from a wide range of relevant disciplines relating to the discovery and development of new drugs in addition to epidemiology and statistics. Scientific Advisors represent various regions around the world and the public, private, and academic sectors.
The new Scientific Advisors are as follows:
Michael Dunne, M.D. (Durata Therapeutics)
Dr. Dunne is Chief Medical Officer at Durata Therapeutics and an expert in clinical development and infectious diseases. Previously, Dr. Dunne worked for Pfizer and was responsible for strategic and operational oversight of the clinical infectious diseases portfolio, which included treatments for bacterial, fungal, and viral infections, including HIV/AIDS. Dr. Dunne is an accomplished scientific author and lecturer and has had significant experience in global and public health activities. In addition to his clinical experience in the pharmaceutical industry, Dr. Dunne spent nine years as an Adjunct Clinical Assistant Professor at Yale University School of Medicine.
Mark J. Goldberger, M.D., M.P.H. (Abbott Laboratories)
Dr. Goldberger is Divisional Vice President for Regulatory Policy and Intelligence Pharmaceutical products Group for Abbott Laboratories and has deep understanding of global regulatory processes. Prior to working for Abbott, Dr. Goldberger spent nearly 20 years at the United States Food and Drug Administration, including the roles of Director of the Office of Antimicrobial Products and Acting Deputy Center Director both within the Center of Drug Evaluation and Research and Medical Director for Emerging and Pandemic Threat Preparedness within the Center for Biologics Evaluation and Research. A prolific presenter and lecturer, Dr. Goldberger obtained his medical degree from Columbia University and his masters of public health from George Washington University.
Paul J. Reider, Ph.D. (Princeton University)
Dr. Reider is currently a Pharmaceutical Specialist and Lecturer in the Department of Chemistry at Princeton University. Prior to joining Princeton, Dr. Reider amassed nearly 30 years of experience working with and managing small molecule development programs, first at Merck where he served as Vice President of Process Research and then later at Amgen as Vice President of Chemistry, Research, and Discovery. Dr. Reider has authored nearly 200 academic papers and has delivered more than 100 guest lectures and speeches. Dr. Reider earned his Ph.D. from the University of Vermont.